Maija Hollmén

3.8k total citations · 1 hit paper
84 papers, 2.5k citations indexed

About

Maija Hollmén is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Maija Hollmén has authored 84 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 38 papers in Immunology and 22 papers in Molecular Biology. Recurrent topics in Maija Hollmén's work include Immune cells in cancer (23 papers), Lymphatic System and Diseases (16 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Maija Hollmén is often cited by papers focused on Immune cells in cancer (23 papers), Lymphatic System and Diseases (16 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Maija Hollmén collaborates with scholars based in Finland, Switzerland and United States. Maija Hollmén's co-authors include Sirpa Jalkanen, Klaus Elenius, Michael Detmar, Sinem Karaman, Heikki Joensuu, Anita I. Kapanen, Jarmo Salo, Jenna H. Rannikko, Jorma Isola and Ylermi Soini and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Maija Hollmén

80 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab

2005 545 citations Maija Hollmén et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maija Hollmén Finland	27	1.3k	883	603	480	305	84	2.5k
Hong Chen China	25	1.5k 1.1×	481 0.5×	840 1.4×	641 1.3×	223 0.7×	108	2.6k
Sharon Gordon United Kingdom	16	1.6k 1.3×	924 1.0×	948 1.6×	388 0.8×	237 0.8×	24	3.5k
Pedro Gascón United States	32	694 0.5×	1.1k 1.2×	529 0.9×	308 0.6×	251 0.8×	60	3.2k
Jun Asai Japan	26	768 0.6×	986 1.1×	345 0.6×	196 0.4×	189 0.6×	78	2.7k
Fabrice Journé Belgium	35	1.1k 0.9×	1.4k 1.6×	616 1.0×	353 0.7×	105 0.3×	113	3.3k
Iris Helfrich Germany	25	644 0.5×	1.3k 1.4×	445 0.7×	273 0.6×	172 0.6×	48	3.0k
Karin Potthoff Germany	20	804 0.6×	828 0.9×	397 0.7×	315 0.7×	327 1.1×	60	2.3k
Hao‐Wei Wang United States	25	979 0.8×	703 0.8×	653 1.1×	175 0.4×	215 0.7×	87	2.4k
Sebastian Theurich Germany	31	1.5k 1.2×	919 1.0×	1.6k 2.6×	264 0.6×	643 2.1×	120	4.1k
Dechun Li China	29	643 0.5×	1.1k 1.2×	484 0.8×	530 1.1×	499 1.6×	96	2.7k

Countries citing papers authored by Maija Hollmén

Since Specialization

Citations

This map shows the geographic impact of Maija Hollmén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maija Hollmén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maija Hollmén more than expected).

Fields of papers citing papers by Maija Hollmén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maija Hollmén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maija Hollmén. The network helps show where Maija Hollmén may publish in the future.

Co-authorship network of co-authors of Maija Hollmén

This figure shows the co-authorship network connecting the top 25 collaborators of Maija Hollmén. A scholar is included among the top collaborators of Maija Hollmén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maija Hollmén. Maija Hollmén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kauko, Anni, Kati Elima, Minna Piipponen, et al.. (2025). Breast cancer remodels lymphatics in sentinel lymph nodes. Nature Communications. 16(1). 10056–10056.

Prince, Stuart, Miro Viitala, Jenna H. Rannikko, et al.. (2025). Secreted Clever-1 modulates T cell responses and impacts cancer immunotherapy efficacy. Theranostics. 15(15). 7501–7527. 3 indexed citations

Zeidan, Amer M., Anthony S. Stein, Johanna Rimpiläinen, et al.. (2025). Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study. Blood. 146(Supplement 1). 236–236. 1 indexed citations

Kuusanmäki, Heikki, Jenna H. Rannikko, Mari Björkman, et al.. (2025). CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies. Scientific Reports. 15(1). 16775–16775. 3 indexed citations

Jalkanen, Juho, Maija Hollmén, Hannu Kokki, et al.. (2024). QClus: a droplet filtering algorithm for enhanced snRNA-seq data quality in challenging samples. Nucleic Acids Research. 53(1). 1 indexed citations

Monfrini, Edoardo, Sara Pelucchi, Maija Hollmén, et al.. (2023). A form of inherited hyperferritinemia associated with bi-allelic pathogenic variants of STAB1. The American Journal of Human Genetics. 110(8). 1436–1443. 1 indexed citations

Kuusanmäki, Heikki, Mari Björkman, Juho Jalkanen, et al.. (2023). Abstract A14: Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer Discovery. 4(3_Supplement). A14–A14. 1 indexed citations

Rinne, Petteri, Jenna H. Rannikko, Maija Hollmén, et al.. (2023). The effect of acute exercise on circulating immune cells in newly diagnosed breast cancer patients. Scientific Reports. 13(1). 6561–6561. 25 indexed citations

Aittokallio, Jenni, Jarmo Gunn, Tuija Vasankari, et al.. (2023). Risk of fluid accumulation after cardiac surgery. JTCVS Open. 16. 602–609. 6 indexed citations

10.

Hollmén, Maija, Mikael Maksimow, Jenna H. Rannikko, et al.. (2022). Nonclinical Characterization of Bexmarilimab, a Clever-1–Targeting Antibody for Supporting Immune Defense Against Cancers. Molecular Cancer Therapeutics. 21(7). 1207–1218. 9 indexed citations

11.

Wolf, Stefan, Jenna H. Rannikko, Reetta Virtakoivu, et al.. (2022). A distinct M2 macrophage infiltrate and transcriptomic profile decisively influence adipocyte differentiation in lipedema. Frontiers in Immunology. 13. 1004609–1004609. 16 indexed citations

12.

Lemoine, Pascale, Nicolas Dauguet, Axelle Loriot, et al.. (2022). BRAFV600E Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages. Cancers. 14(19). 4687–4687. 2 indexed citations

13.

Virtakoivu, Reetta, et al.. (2022). Clever-1 positive macrophages in breast cancer. Breast Cancer Research and Treatment. 195(3). 237–248. 7 indexed citations

14.

Vaura, Felix, et al.. (2021). Novel Biomarkers for Diagnosing Periprosthetic Joint Infection from Synovial Fluid and Serum. JBJS Open Access. 6(2). 15 indexed citations

15.

Virtakoivu, Reetta, Jenna H. Rannikko, Miro Viitala, et al.. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical Cancer Research. 27(15). 4205–4220. 41 indexed citations

16.

Bono, Petri, Panu Jaakkola, Shishir Shetty, et al.. (2020). 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. Annals of Oncology. 31. S706–S707. 1 indexed citations

17.

Viitala, Miro, et al.. (2019). Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors. Clinical Cancer Research. 25(11). 3289–3303. 82 indexed citations

18.

Hollmén, Maija, et al.. (2018). Serum cytokine levels differ according to major cardiovascular risk factors in patients with lower limb atherosclerosis. Cytokine. 114. 74–80. 9 indexed citations

19.

Karikoski, Marika, Fumiko Marttila‐Ichihara, Kati Elima, et al.. (2014). Clever-1/Stabilin-1 Controls Cancer Growth and Metastasis. Clinical Cancer Research. 20(24). 6452–6464. 77 indexed citations

20.

Karaman, Sinem, Maija Hollmén, Marius R. Robciuc, et al.. (2014). Blockade of VEGF-C and VEGF-D modulates adipose tissue inflammation and improves metabolic parameters under high-fat diet. Molecular Metabolism. 4(2). 93–105. 88 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact